Actively Recruiting
Evaluating Tezepelumab Treatment and Step-Down of Maintenance Therapy in Patients with Severe Asthma in China
Led by AstraZeneca · Updated on 2026-11-04
400
Participants Needed
75
Research Sites
59 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the potential for Tezepelumab to help patients with severe asthma reduce their background maintenance medications while maintaining control of their asthma symptoms. This Phase 3b, single-arm study involves about 400 Chinese patients with severe asthma who are currently on medium to high doses of inhaled corticosteroids and long-acting beta-agonists, with or without additional controllers. The study aims to assess the safety and effectiveness of stepping down therapy after starting Tezepelumab. Participants will receive Tezepelumab treatment while their current asthma controller medications are gradually reduced under medical supervision. The study lasts up to 52 weeks and is conducted at approximately 70 sites in China. Patients continue on medium-high dose ICS-LABA with up to one additional controller at enrollment, and the study evaluates how well asthma control is maintained during and after the medication reduction. Throughout the study, participants will attend regular visits for assessments of lung function, asthma symptom control using questionnaires like the Asthma Control Questionnaire-5 and St. Georges Respiratory Questionnaire, and biomarkers related to severe asthma. Researchers will also monitor asthma exacerbations, nasal symptoms for those with comorbid nasal polyps, and daily symptoms through diaries. Safety and treatment adherence are closely tracked over the year-long study period.
CONDITIONS
Brief Title
Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab
Research Team
A
AstraZeneca Clinical Study Information Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here